DOCSLIB.ORG

FTSE 100 Index Data As At: 31 August 2021 Bmktitle1 the FTSE 100 Is a Market-Capitalisation Weighted Index of UK-Listed Blue Chip Companies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FTSE 100 Index Data As At: 31 August 2021 Bmktitle1 the FTSE 100 Is a Market-Capitalisation Weighted Index of UK-Listed Blue Chip Companies FTSE Russell Factsheet FTSE 100 Index Data as at: 31 August 2021 bmkTitle1 The FTSE 100 is a market-capitalisation weighted index of UK-listed blue chip companies. The FEATURES index is part of the FTSE UK Series and is designed to measure the performance of the 100 largest companies traded on the London Stock Exchange that pass screening for size and Objective liquidity. FTSE 100 constituents are all traded on the London Stock Exchange’s SETS trading The index is designed for use in the creation system. of index tracking funds, derivatives and as a 10-Year Performance - Total Return performance benchmark. (GBP) Investability 400 Stocks are selected and weighted to ensure 350 300 that the index is investable. 250 Liquidity 200 Stocks are screened to ensure that the index 150 is tradable. 100 50 Transparency Aug-2011 Aug-2012 Aug-2013 Aug-2014 Aug-2015 Aug-2016 Aug-2017 Aug-2018 Aug-2019 Aug-2020 Aug-2021 Data as at month end The index uses a transparent, rules-based construction process. Index Methodologies FTSE 100 FTSE 250 FTSE SmallCap FTSE All-Share FTSE Fledgling are freely available on the FTSE Russell website. Performance and Volatility - Total Return Availability Index (GBP) Return % Return pa %* Volatility %** The index is calculated based on price and 3M 6M YTD 12M 3YR 5YR 3YR 5YR 1YR 3YR 5YR total return methodologies, both real time FTSE 100 2.5 12.4 13.3 23.6 7.5 27.5 2.4 5.0 15.0 19.7 13.6 intra-second and end of day. FTSE 250 6.8 16.6 19.3 38.2 25.2 54.3 7.8 9.1 14.6 25.5 16.9 Industry Classification Benchmark FTSE SmallCap 5.7 19.2 24.7 52.9 42.3 79.9 12.5 12.5 11.0 22.5 16.1 (ICB) FTSE All-Share 3.4 13.3 14.7 26.9 11.4 33.3 3.7 5.9 14.4 20.2 13.9 Index constituents are categorized in FTSE Fledgling 3.3 20.0 26.1 56.5 27.0 82.8 8.3 12.8 7.8 20.4 19.1 accordance with the Industry Classification * Compound annual returns measured over 3 and 5 years respectively Benchmark (ICB), the global standard for ** Volatility – 1YR based on 12 months daily data. 3YR based on weekly data (Wednesday to Wednesday). 5YR based on monthly data industry sector analysis. Year-on-Year Performance - Total Return Index % (GBP) 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 FTSE 100 -2.2 10.0 18.7 0.7 -1.3 19.1 11.9 -8.7 17.3 -11.5 FTSE 250 -10.1 26.1 32.3 3.7 11.2 6.7 17.8 -13.3 28.9 -4.6 FTSE SmallCap -12.5 27.8 32.8 0.9 9.2 14.3 18.2 -9.5 18.8 7.1 FTSE All-Share -3.5 12.3 20.8 1.2 1.0 16.8 13.1 -9.5 19.2 -9.8 FTSE Fledgling -12.6 19.8 39.0 8.8 15.4 18.2 26.4 -7.3 2.3 11.0 Source: FTSE Russell as at 31 August 2021. Past performance is no guarantee of future results. 1 of 3 Returns shown before the index launch date reflect hypothetical historical performance. Please see disclaimer for important legal information. FTSE 100 Index Data as at: 31 August 2021 Return/Risk Ratio and Drawdown - Total Return INFORMATION Index (GBP) Return/Risk Ratio Drawdown (%) Index Universe 1YR 3YR 5YR 10YR 1YR 3YR 5YR 10YR FTSE All-Share Index FTSE 100 1.5 0.1 0.4 0.5 -8.5 -34.2 -34.2 -34.2 FTSE 250 2.5 0.3 0.5 0.8 -5.6 -41.7 -41.7 -41.7 Index Launch FTSE SmallCap 4.6 0.5 0.8 0.9 -3.9 -39.8 -39.8 -39.8 3 January 1984 FTSE All-Share 1.8 0.2 0.4 0.6 -7.3 -35.3 -35.3 -35.3 Base Date FTSE Fledgling 7.0 0.4 0.7 0.9 -2.6 -44.5 -44.7 -44.7 30 December 1983 Return/Risk Ratio – based on compound annual returns and volatility in Performance and Volatility table Base Value Drawdown - based on daily data 1000 Top 5 Constituents Investability Screen Constituent ICB Sector Net MCap (GBPm) Wgt % Actual free float applied and liquidity AstraZeneca Pharmaceuticals and Biotechnology 131,690 6.81 screened Unilever Personal Care Drug and Grocery Stores 105,527 5.46 Diageo Beverages 80,190 4.15 Index Calculation HSBC Hldgs Banks 78,865 4.08 Real-time and end-of-day index available GlaxoSmithKline Pharmaceuticals and Biotechnology 72,223 3.73 End-of-Day Distribution Totals 468,495 24.23 Via FTP and email ICB Supersector Breakdown Currency FTSE 100 FTSE All-Share Sterling and Euro ICB Code ICB Supersector No. of Net MCap (GBPm) Wgt % No. of Net MCap (GBPm) Wgt % Review Dates Cons Cons 1010 Technology 5 33,987 1.76 21 50,302 2.05 Quarterly in March, June, September, 1510 Telecommunications 2 49,019 2.53 7 53,791 2.19 December 2010 Health Care 4 220,446 11.40 14 239,296 9.75 Historical Data 3010 Banks 5 163,912 8.48 11 172,184 7.02 Available from January 1984 3020 Financial Services 10 100,890 5.22 228 281,268 11.46 3030 Insurance 5 82,888 4.29 13 98,521 4.01 3510 Real Estate 4 31,323 1.62 56 80,496 3.28 4010 Automobiles and Parts - - - 2 2,195 0.09 4020 Consumer Products and Services 6 63,032 3.26 22 85,473 3.48 4030 Media 5 70,110 3.63 11 77,133 3.14 4040 Retailers 4 27,400 1.42 22 53,304 2.17 4050 Travel and Leisure 5 55,507 2.87 33 85,660 3.49 4510 Food Beverage and Tobacco 5 168,968 8.74 18 182,252 7.43 Personal Care Drug and Grocery 4520 5 174,852 9.04 9 184,916 7.53 Stores 5010 Construction and Materials 1 30,317 1.57 15 42,126 1.72 5020 Industrial Goods and Services 18 210,707 10.90 72 285,160 11.62 5510 Basic Resources 8 197,598 10.22 18 205,025 8.35 5520 Chemicals 2 17,885 0.92 7 24,430 1.00 6010 Energy 3 170,795 8.83 14 176,897 7.21 6510 Utilities 4 64,243 3.32 10 73,980 3.01 Totals 101 1,933,879 100.00 603 2,454,409 100.00 Source: FTSE Russell as at 31 August 2021. Past performance is no guarantee of future results. 2 of 3 Returns shown before the index launch date reflect hypothetical historical performance. Please see disclaimer for important legal information. FTSE 100 Index Data as at: 31 August 2021 Index Characteristics Attributes FTSE 100 Number of constituents 101 Net MCap (GBPm) 1,933,879 Dividend Yield % 3.28 Constituent Sizes (Net MCap GBPm) Average 19,147 Largest 131,690 Smallest 1,573 Median 9,706 Weight of Largest Constituent (%) 6.81 Top 10 Holdings (% Index MCap) 39.30 31 August 2021 bmkImage1 bmkImage2 bmkImage3 © 2021 London Stock Exchange Group plc and its applicable group undertakings (the “LSE Group”). The LSE Group includes (1) FTSE International Limited (“FTSE”), (2) Frank Russell Company (“Russell”), (3) FTSE Global Debt Capital Markets Inc. and FTSE Global Debt Capital Markets Limited (together, “FTSE Canada”), (4) MTSNext Limited (“MTSNext”), (5) Mergent, Inc. (“Mergent”), (6) FTSE Fixed Income LLC (“FTSE FI”), (7) The Yield Book Inc (“YB”) and (8) Beyond Ratings S.A.S. (“BR”). All rights reserved. FTSE Russell® is a trading name of FTSE, Russell, FTSE Canada, MTSNext, Mergent, FTSE FI, YB and BR. “FTSE®”, “Russell®”, “FTSE Russell®”, “MTS®”, “FTSE4Good®”, “ICB®”, “Mergent®”, “The Yield Book®”, “Beyond Ratings®” and all other trademarks and service marks used herein (whether registered or unregistered) are trademarks and/or service marks owned or licensed by the applicable member of the LSE Group or their respective licensors and are owned, or used under licence, by FTSE, Russell, MTSNext, FTSE Canada, Mergent, FTSE FI, YB or BR. FTSE International Limited is authorised and regulated by the Financial Conduct Authority as a benchmark administrator. All information is provided for information purposes only. All information and data contained in this publication is obtained by the LSE Group, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error as well as other factors, however, such information and data is provided "as is" without warranty of any kind. No member of the LSE Group nor their respective directors, officers, employees, partners or licensors Data definitions available from make any claim, prediction, warranty or representation whatsoever, expressly or impliedly, either as to the accuracy, timeliness, completeness, merchantability of any information or of results to be obtained from the use of FTSE Russell products, including but not limited to indexes, data and [email protected] analytics, or the fitness or suitability of the FTSE Russell products for any particular purpose to which they might be put. Any representation of historical data accessible through FTSE Russell products is provided for information purposes only and is not a reliable indicator of future performance. To learn more, visit www.ftserussell.com; No responsibility or liability can be accepted by any member of the LSE Group nor their respective directors, officers, employees, partners or licensors for (a) email [email protected]; or any loss or damage in whole or in part caused by, resulting from, or relating to any error (negligent or otherwise) or other circumstance involved in call your regional Client Services Team office: procuring, collecting, compiling, interpreting, analysing, editing, transcribing, transmitting, communicating or delivering any such information or data or from use of this document or links to this document or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if any member of EMEA the LSE Group is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, such information.
Load more

Recommended publications
  • Corporate Governance
    Strategic report Governance and remuneration Financial statements Investor information Corporate Governance In this section Chairman’s Governance statement 78 The Board 80 Corporate Executive Team 83 Board architecture 85 Board roles and responsibilities 86 Board activity and principal decisions 87 Our purpose, values and culture 90 The Board’s approach to engagement 91 Board performance 94 Board Committee information 96 Our Board Committee reports 97 Section 172 statement 108 Directors’ report 109 GSK Annual Report 2020 77 Chairman’s Governance statement In last year’s Governance statement, I explained that our primary Education and focus on Science objective for 2020 was to ensure there was clarity between the Given the critical importance of strengthening the pipeline, Board and management on GSK’s execution of strategy and its the Board has benefitted from devoting a higher proportion of operational priorities. We have aligned our long-term priorities its time in understanding the science behind our strategy and of Innovation, Performance and Trust powered by culture testing its application. It is important that the Board has a and agreed on the metrics to measure delivery against them. working understanding of the key strategic themes upon The Board’s annual cycle of meetings ensures that all major which our R&D strategy is based. These themes have been components of our strategy are reviewed over the course complemented by Board R&D science thematic deep dives. of the year. Our focus was on the fundamentals of our strategy: human The COVID-19 pandemic impacted and dominated all our genetics, the immune system and AI and ML, as well as to lives for the majority of 2020.
    [Show full text]
  • Midwest Financial Brian Johnson, RFC 706 Montana Street Glidden, IA 51443 [email protected] 712-659-2156
    Midwest Financial Brian Johnson, RFC 706 Montana Street Glidden, IA 51443 www.midwestfinancial.us [email protected] 712-659-2156 The SITREP for the week ending 08/06/2021 ***************************************************** SIT REP: n. a report on the current situation; a military abbreviation; from "situation report". In the markets: U.S. Markets: U.S. stocks recorded solid gains for the week and several indices hit record highs. The Dow Jones Industrial Average rose 273 points finishing the week at 35,209, a gain of 0.8%. The NASDAQ retraced all of last week’s decline by rising 1.1% to close at 14,836. By market cap, the large cap S&P 500 rose 0.9%, while the mid cap S&P 400 and small cap Russell 2000 gained 0.5% and 1.0%, respectively. International Markets: Major international markets also finished the week solidly in the green. Canada’s TSX added 0.9%, while the United Kingdom’s FTSE 100 gained 1.3%. France’s CAC 40 and Germany’s DAX rose 3.1% and 1.4%, respectively. China’s Shanghai Composite added 1.8%, while Japan’s Nikkei rallied 2%. As grouped by Morgan Stanley Capital International, developed markets finished up 1.0% and emerging markets gained 0.7%. Commodities: Precious metals had a difficult week. Gold retreated -3.0% to $1763.10 per ounce, while Silver fell a steeper -4.8% to $24.33. West Texas Intermediate crude oil gave up all of the last two week’s gains, declining -7.7% to $68.28 per barrel. The industrial metal copper, viewed by some analysts as a barometer of world economic health due to its wide variety of uses, finished the week down -3%.
    [Show full text]
  • In the United States District Court for the District Of
    IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE FOREST LABORATORIES, LLC and ) FOREST LABORATORIES ) HOLDINGS, LTD., ) ) Plaintiffs, ) ) v. ) Civ.No.14-1119-SLR ) SIGMAPHARM LABORATORIES, LLC, ) et al., ) ) Defendants. ) Jack B. Blumenfeld, Esquire and Maryellen Noreika, Esquire of Morris, Nichols, Arsht & Tunnell LLP, Wilmington, Delaware. Counsel for Plaintiffs. Of Counsel: Howard W. Levine, Esquire, Sanya Sukduang, Esquire, Jonathan R. Davies, Esquire, Courtney B. Gasp, Esquire, and Charles E. Lipsey, Esquire of Finnegan, Henderson, Farabow, Garrett & Dunner LLP. John C. Phillips, Esquire, David A. Bilson, Esquire and Megan C. Haney of Phillips, Goldman, Mclaughlin & Hall, P.A., Wilmington, Delaware. Counsel for Defendant Sigmapharm Laboratories, LLC. Of Counsel: Anthony G. Simon, Esquire, Anthony R. Friedman, Esquire, Benjamin R. Askew, Esquire, and Michael P. Kella, Esquire of The Simon Law Firm, P.C. Karen Elizabeth Keller, Esquire and Jeffrey Thomas Castellano, Esquire of Shaw Keller, LLP, Wilmington, Delaware. Counsel for Defendants Hikma Pharmaceuticals LLC, Hikma Pharmaceuticals PLC, and West-Ward Pharmaceutical Corp. Of Counsel: lmron T. Aly, Esquire, Joel M. Wallace, Esquire, and Helen H. Ji, Esquire of Schiff Hardin LLP. Richard D. Kirk, Esquire, Stephen B. Brauerman, Esquire and Sara E. Bussiere, Esquire of Bayard, P.A., Wilmington, Delaware. Counsel for Defendant Breckenridge Pharmaceutical, Inc. Of Counsel: Beth D. Jacob, Esquire, Clifford Katz, Esquire, and Malavika A. Rao, Esquire of Kelley, Drye & Warren LLP. Karen Pascale, Esquire and Pilar G. Kraman, Esquire of Young, Conaway, Stargatt & Taylor, LLP, Wilmington, Delaware. Counsel for Defendants Alembic Pharmaceuticals Ltd., Alembic Global Holding SA and Alembic Pharmaceuticals, Inc. Of Counsel: Steven J. Lee, Esquire, Michael K.
    [Show full text]
  • PEDIARIX Is a Vaccine
    HIGHLIGHTS OF PRESCRIBING INFORMATION • If Guillain-Barré syndrome occurs within 6 weeks of receipt of a prior These highlights do not include all the information needed to use vaccine containing tetanus toxoid, the decision to give PEDIARIX should PEDIARIX safely and effectively. See full prescribing information for be based on potential benefits and risks. (5.2) PEDIARIX. • The tip caps of the prefilled syringes contain natural rubber latex which may cause allergic reactions. (5.3) PEDIARIX [Diphtheria and Tetanus Toxoids and Acellular Pertussis • Syncope (fainting) can occur in association with administration of Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus injectable vaccines, including PEDIARIX. Procedures should be in place Vaccine], Suspension for Intramuscular Injection to avoid falling injury and to restore cerebral perfusion following Initial U.S. Approval: 2002 syncope. (5.4) • If temperature ≥105°F, collapse or shock-like state, or persistent, ----------------------------- INDICATIONS AND USAGE ---------------------------- PEDIARIX is a vaccine indicated for active immunization against diphtheria, inconsolable crying lasting ≥3 hours have occurred within 48 hours after tetanus, pertussis, infection caused by all known subtypes of hepatitis B virus, receipt of a pertussis-containing vaccine, or if seizures have occurred and poliomyelitis. PEDIARIX is approved for use as a 3-dose series in infants within 3 days after receipt of a pertussis-containing vaccine, the decision born of hepatitis B surface antigen (HBsAg)-negative mothers. PEDIARIX to give PEDIARIX should be based on potential benefits and risks. (5.5) may be given as early as 6 weeks of age through 6 years of age (prior to the • For children at higher risk for seizures, an antipyretic may be 7th birthday).
    [Show full text]
  • Preclinical Development & IND Filing: Nuts, Bolts, Best Practices
    “Preclinical Development & IND Filing: Nuts, Bolts, Best Practices and Regulatory Aspects.” Speakers: Amit Kalgutkar (Pfizer), Chandra Prakash (Agios), Sanjeev Thohan (Novartis), Li- Chun Wang (Takeda), Wei Yin (Biogen) Organizers: Sanjeev Thohan and Chandra Prakash Date: 6/29/2017 Time: 8:30 am – 5.00 pm Location: Boston/Cambridge Area: Marriott Kendall Square, 50 Broadway, Cambridge MA 02142 Fees: $175 - Regular (before June 1st, 2017), $225 - Regular (after June 1st, 2017); $125 - Unemployed & Academic; $2000 - Major Sponsorship; $475 - Vendor Show Registration: www.PBSS.org Workshop Description: An investigational new drug application (IND) is an important milestone that marks the entry of a molecule into clinical development. Knowing the objectives, expectations and processes of assembling an IND is a key to not only successful filing, but also a promising clinical development path forward. Often there are cases where too many of our “nice-to-have” studies crowd the package at the expense of critical study needs/issues. This can lead to significant delays in clinical developments with back-and-forth of Q&A sessions both internally and with regulatory agencies. As we have seen, the regulatory landscape is changing as rapidly as the industry innovates into new therapeutic modalities. Therefore, it is critical to keep up to date on regulatory requirements and the industry’s best practices in different aspects of the IND: non- clinical safety, PK, CMC, and clinical plans. In this workshop, our speakers who bring years of experience with multiple successful IND filings, will discuss systematically the preclinical studies required for small molecule IND’s as well as the nuts and bolts of putting together a high–quality IND package.
    [Show full text]
  • Scanned Image
    3130 W 57th St, Suite 105 Sioux Falls, SD 57108 Voice: 605-373-0201 Fax: 605-271-5721 [email protected] www.greatplainsfa.com Securities offered through First Heartland Capital, Inc. Member FINRA & SIPC. Advisory Services offered through First Heartland Consultants, Inc. Great Plains Financial Advisors, LLC is not affiliated with First Heartland Capital, Inc. In this month’s recap: the Federal Reserve eases, stocks reach historic peaks, and face-to-face U.S.-China trade talks formally resume. Monthly Economic Update Presented by Craig Heien with Great Plains Financial Advisors, August 2019 THE MONTH IN BRIEF July was a positive month for stocks and a notable month for news impacting the financial markets. The S&P 500 topped the 3,000 level for the first time. The Federal Reserve cut the country’s benchmark interest rate. Consumer confidence remained strong. Trade representatives from China and the U.S. once again sat down at the negotiating table, as new data showed China’s economy lagging. In Europe, Brexit advocate Boris Johnson was elected as the new Prime Minister of the United Kingdom, and the European Central Bank indicated that it was open to using various options to stimulate economic activity.1 DOMESTIC ECONOMIC HEALTH On July 31, the Federal Reserve cut interest rates for the first time in more than a decade. The Federal Open Market Committee approved a quarter-point reduction to the federal funds rate by a vote of 8-2. Typically, the central bank eases borrowing costs when it senses the business cycle is slowing. As the country has gone ten years without a recession, some analysts viewed this rate cut as a preventative measure.
    [Show full text]
  • Assessment Report COVID-19 Vaccine Astrazeneca EMA/94907/2021
    29 January 2021 EMA/94907/2021 Committee for Medicinal Products for Human Use (CHMP) Assessment report COVID-19 Vaccine AstraZeneca Common name: COVID-19 Vaccine (ChAdOx1-S [recombinant]) Procedure No. EMEA/H/C/005675/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 7 1.1. Submission of the dossier ..................................................................................... 7 1.2. Steps taken for the assessment of the product ........................................................ 9 2. Scientific discussion .............................................................................. 12 2.1. Problem statement ............................................................................................. 12 2.1.1. Disease or condition ........................................................................................ 12 2.1.2. Epidemiology and risk factors ........................................................................... 12 2.1.3. Aetiology and pathogenesis .............................................................................
    [Show full text]
  • Final Attendee List
    Jennifer Abnet GlaxoSmithKline I GlaxoSmithKline I Jane Arboleda APRN Guardant I Molly Benson Sanjiv Agarwala MD Puma Biotechnology I Cancer Expert Now I Joe Arminger AbbVie I Seth Berkowitz LCSW, Manmeet Ahluwalia MD, CCLS MBA Patricia Armstrong The Leukemia & Lymphoma Miami Cancer Institute I Novartis I Society V Steve Albers Kim Arnold APRN CPNP Barry Berman MD, MS Alexion V CPHON Florida Cancer Specialists I Servier Pharmaceuticals I Maritza Alencar DNP, Tizano Bernard MBA, APRN, BMTCN Sheila Arrington MSN, Cancer Care Centers of Miami Cancer Institute V APRN, NP-C, AOCN Brevard I Puma Biotechnology I Carmen Allen MSIT Ana Mari Bernardini Pharmavoxx V Shannon Ashmon Novartis Oncology I Eisai, Inc I Luly Almeida Bernard Berry MBA Incyte Corporation I Sarah Ashton MS AstraZeneca Pharmaceuticals Guardant Health I I Talat Almukhtar MD Orlando Health Cancer Melissa Austin Jason Bever Institute I Cancer Care Centers of Oncopeptides I Brevard I Beatrice Alvarado Roberts Amy Bignon MD Garland Avera Doyle Caris Life Sciences I University of Florida I Jazz Pharmaceuticals I Nadeem Bilani MD Tadeu Ambros MD Francie Babcock Cleveland Clinic I FCS I AMAG Pharmaceuticals/Covis I Angela Bilik RN BSN Douglas Anderson AstraZeneca I Incyte Corporation I Craig Bailey Astra Zeneca I Jamie Bilsky BS Blesson Andrews Genentech V Genentech I Kevin Barr Daiichi Sankyo I Rohit Bishnoi MD Ollie Annum PharmD University of Florida I BHMCR I Leonard Bennett PharmD EMD Serono I Brady Blackman Susmitha Apuri MD MorphoSys I Florida Cancer Specialists I Michael Bennett As of 4-22-21 Kimberly Blandon RN MSN Rick Breitenstein Memorial Cancer Institute I Apellis Pharmaceuticals I Denise Capo Karyopharm Therapeutics I Taryn Boiteau GlaxoSmithKline I Amanda Bridges Florida Society of Clinical Heidi Caravetta Tracy Bonds RN, BSN, Oncology I Exelixis, Inc.
    [Show full text]
  • Astrazeneca-Oxford Vaccine Approved for Use in the U.K
    P2JW366000-6-A00100-17FFFF5178F ****** THURSDAY,DECEMBER 31,2020~VOL. CCLXXVI NO.154 WSJ.com HHHH $4.00 DJIA 30409.56 À 73.89 0.2% NASDAQ 12870.00 À 0.2% STOXX 600 400.25 g 0.3% 10-YR. TREAS. À 3/32 , yield 0.926% OIL $48.40 À $0.40 GOLD $1,891.00 À $10.50 EURO $1.2300 YEN 103.21 Deadly Attack at Airport Targets New Yemen Government U.S. IPO What’s News Market Reaches Business&Finance Record nvestorspiled into IPOs Iat a record rate in 2020, with companies raising Total $167.2 billion via 454 of- ferings on U.S. exchanges this year through Dec. 24. Few see signs of letup Few expect the euphoria after companies raise to wear off soon. A1 more than $167 billion Detenteisending in the global fight over tech taxes, despite pandemic with Franceresuming collec- tion of itsdigital-services tax BY MAUREEN FARRELL and the U.S. poised to retali- atewith tariffs.Other coun- Defying expectations,inves- tries areset to join the fray. A1 S tors piled intoinitial public of- China finished 2020 PRES feringsatarecordrateiN with a 10th consecutive TED 2020, and few expect the eu- month of expansion in its CIA phoria to wear off soon. manufacturing sector. A7 SO Companies raised $167.2 AS TheEUand China agreed TENSIONS HIGH: People fled after an explosion Wednesday at the airport in Aden, Yemen, moments after members of the billion through 454 offerings in principle on an invest- country’s newly sworn-in cabinet arrived. At least 22 people were killed, but all the members of the cabinet were safe.
    [Show full text]
  • GLAXOSMITHKLINE LLC V. TEVA PHARMACEUTICALS USA, INC
    Case: 18-1976 Document: 111 Page: 1 Filed: 10/02/2020 United States Court of Appeals for the Federal Circuit ______________________ GLAXOSMITHKLINE LLC, SMITHKLINE BEECHAM (CORK) LIMITED, Plaintiffs-Appellants v. TEVA PHARMACEUTICALS USA, INC., Defendant-Cross-Appellant ______________________ 2018-1976, 2018-2023 ______________________ Appeals from the United States District Court for the District of Delaware in No. 1:14-cv-00878-LPS-CJB, Chief Judge Leonard P. Stark. ______________________ Decided: October 2, 2020 ______________________ JUANITA ROSE BROOKS, Fish & Richardson, PC, San Diego, CA, argued for plaintiffs-appellants. Also represented by MICHAEL ARI AMON, CRAIG E. COUNTRYMAN, JONATHAN ELLIOT SINGER; ELIZABETH M. FLANAGAN, MICHAEL J. KANE, WILLIAM WOODFORD, Minneapolis, MN; DOUGLAS E. MCCANN, Wilmington, DE. WILLIAM M. JAY, Goodwin Procter LLP, Washington, DC, argued for defendant-cross-appellant. Also represented by JAIME ANN SANTOS; ELAINE BLAIS, J. Case: 18-1976 Document: 111 Page: 2 Filed: 10/02/2020 2 GLAXOSMITHKLINE LLC v. TEVA PHARMACEUTICALS USA, INC. ANTHONY DOWNS, ROBERT FREDERICKSON, III, CHRISTOPHER T. HOLDING, ALEXANDRA LU, LANA S. SHIFERMAN, DARYL L. WIESEN, Boston, MA; IRA J. LEVY, New York, NY. HANSJORG SAUER, Biotechnology Innovation Organization, Washington, DC, for amicus curiae Biotechnology Innovation Organization. Also represented by MELISSA A. BRAND; BRIAN PAUL BARRETT, Eli Lilly and Company, Indianapolis, IN. MICHAEL N. KENNEDY, Covington & Burling LLP, Washington, DC, for amicus curiae Pharmaceutical Research and Manufacturers of America. Also represented by STEVEN JOHN WINKELMAN; DAVID EVAN KORN, Pharmaceutical Research and Manufacturers Association of America, Washington, DC. ANDREW CURTIS NICHOLS, Winston & Strawn LLP, Washington, DC, for amicus curiae Association for Accessible Medicines. Also represented by GEORGE C.
    [Show full text]
  • FRC Board Diversity and Effectiveness in FTSE 350
    Leadership Institute Board Diversity and Effectiveness in FTSE 350 Companies July 2021 Acknowledgements Report written by: Mary Akimoto, Osman Anwar, Molly Broome, Dragos Diac, Dr Randall S Peterson, Dr Sergei Plekhanov, Simon Osborne and Vyla Rollins We thank the following individuals on the joint LBSLI/SQW research team for their contributions to this research: • Ruth Cluness, LBSLI • Tom Gosling, LBSLI • Brent Hamerla, LBSLI • Letitia Joseph, LBSLI • Barbara Moorer, LBSLI • Andrei Visiteu, LBSLI • Desi Zlatanova, LBSLI We also give a special thank you to our team of research interviewers: • Eva Beazley • Helen Beedham • Christine de Largy • Kathryn Gordon • Dr JoEllyn Prouty McLaren The London Business School Leadership Institute expresses its thanks to all of our stakeholder and collaborators, who supported our research efforts. We would like to express our specific gratitude to the following individuals, for their invaluable guidance, comments, suggestions and support throughout this project: Kit Bingham, Charlie Brown, Gerry Brown, Sue Clark, Louis Cooper, John Dore, Lisa Duke, Roshy Dwyer, Farrer & Co (Anisha Birk, Natalie Rimmer, Peter Wienand), Louise Fowler, Dr Julian Franks, Dr Karl George MBE, Dr Tom Gosling, Dr Byron Grote, Fiona Hathorn, Jonathan Hayward, Susan Hooper, Dr Ioannis Ioannou, Bernhard Kerres, LBS Accounts department (Akposeba Mukoro, Janet Nippard), LBS Advancement department (Luke Ashby, Susie Balch, Nina Bohn, Ian Frith, Sarah Jeffs, Maria Menicou), LBS Executive Education, LBS Research & Faculty Office and
    [Show full text]
  • United States District Court for the District of Columbia
    Case 1:12-cv-00472-BAH Document 42 Filed 07/05/12 Page 1 of 49 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA ASTRAZENECA PHARMACEUTICALS LP, Plaintiff, v. Civil Action No. 12-00472 (BAH) Judge Beryl A. Howell FOOD AND DRUG ADMINISTRATION, et al., Defendants. AMENDED MEMORANDUM OPINION Plaintiff AstraZeneca Pharmaceuticals LP (“AstraZeneca”) has manufactured the drug quetiapine fumarate (“quetiapine”) under the brand name Seroquel® (“Seroquel”) since 1997 without generic competition. AstraZeneca brought this lawsuit, which presents a question of statutory interpretation, against the Food and Drug Administration, Margaret A. Hamburg, M.D., Commissioner of Food and Drugs, and Kathleen Sebelius, Secretary of Health and Human Services (collectively, “the FDA”), to challenge the FDA’s approval, on March 27, 2012, of generic versions of Seroquel. See Complaint, ECF No. 1 (“Compl.”), ¶ 3. AstraZeneca believes that, under the plain language of 21 U.S.C. § 355(j)(5)(F)(iv), codifying Section 505(j)(5)(F)(iv) of the Federal Food, Drug, and Cosmetic Act (“FDCA”), it is entitled to total market exclusivity until December 2, 2012 for the safety information encapsulated in “Table 2,” which was approved for all Seroquel labels on December 2, 2009 and must be included on the labels of all generic versions of quetiapine. Based upon this belief, AstraZeneca seeks a judgment that the FDA’s recent approval of generic versions of quetiapine, while AstraZeneca retains exclusivity over Table 2, violated AstraZeneca’s exclusivity rights and was arbitrary, capricious, and contrary to law. 1 Case 1:12-cv-00472-BAH Document 42 Filed 07/05/12 Page 2 of 49 Pending before the Court are Cross-Motions for Summary Judgment filed by AstraZeneca, ECF No.
    [Show full text]